Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of R-ketamine (HR071603) Nasal Spray in Healthy Subjects
NCT04108234Phase 1Completed
- Sponsor
- Hengrui
- Start
- Oct 2019
- Primary completion
- Jun 2021
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing HR071603 (Arketamine) with Placebo (2 arms). Primary endpoint: Incidence of Adverse Events (Safety and Tolerability). Started Oct 2019; status: completed.
02
Drugs
r-ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04108234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04108234.